Can a Triple-Drug combo outsmart Immunotherapy-Resistant lung cancer?
NCT ID NCT03220477
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether combining three drugs—pembrolizumab, guadecitabine, and mocetinostat—can safely treat advanced non-small cell lung cancer (NSCLC) in people whose cancer has progressed after prior immunotherapy. The study aims to find the safest doses of guadecitabine and mocetinostat when given alongside a standard dose of pembrolizumab, and to see if the combination has any effect on tumors. Participants receive the drugs in cycles, with careful monitoring for side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of three drugs: pembrolizumab (given by vein), guadecitabine (given as a shot under the skin), and mocetinostat (taken as a pill).
- What this could lead to
- If this combination proves safe and shows promise, it could offer a new treatment option for people with advanced lung cancer whose disease has worsened despite prior immunotherapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits are uncertain. The drugs may cause significant side effects, and the combination might not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111-2497, United States
-
John Hopkins Medical Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection